Podcasts

Episode 69 | The Evolving Landscape of BRAF-Mutated NSCLC in Australia

Host A/Prof Rachel Roberts-Thomson leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer.

Episode Summary

In this episode of TOGA’s Conversations in Lung Cancer Research, host A/Prof Rachel Roberts-Thomson, a Medical Oncologist at The Queen Elizabeth Hospital and Cancer Care Adelaide, leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer. Joined by Prof Myung-Ju Ahn, a Medical Oncologist at Hanyang University Medical Centre in South Korea as well as Co-chair for the upcoming World Lung Cancer Conference, and A/Prof Adnan Nagrial, a Medical Oncologist at Westmead Hospital in Sydney. The panel discusses the clinical characteristics and incidence of this molecular subset, the critical need for upfront comprehensive genomic testing, key clinical trial data for targeted therapies, and practical strategies for managing treatment-specific side effects like pyrexia syndrome.

This episode is sponsored by Pierre Fabre.

Speakers

  • A/Prof Rachel Roberts-Thomson, Medical Oncologist, The Queen Elizabeth Hospital and Cancer Care Adelaide
  • Prof Myung-Ju Ahn, Medical Oncologist, Hanyang University Medical Centre, South Korea
  • A/Prof Adnan Nagrial, Medical Oncologist, Westmead Hospital

Play Episode 69 | The Evolving Landscape of BRAF-Mutated NSCLC in Australia

More Podcasts

Host A/Prof Steven Kao is joined by A/Prof Venessa Chin and Dr Ben Kong,
Host A/Prof Mel Moore interviews Prof Zarnie Lwin OAM, University of Queensland; Medical Oncologist at Royal Brisbane and Women’s Hospital and The Prince Charles Hospital.
A/Prof Gavin Wright sits down with a multidisciplinary panel of experts to tackle the critical and complex issue of smoking-related stigma in lung cancer.
Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.
Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.
Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.